Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 6/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5323766 | 1.00 | DPP7 (0.46) | DPP7ATMDPP4MMP1MMP2 | |
| SCHEMBL3067848 | 0.83 | DPP7 (0.56) | DPP7ATMDPP4MMP1MMP2 | |
| SCHEMBL3062191 | 0.81 | CYP3A4 (0.42) | MMP1MMP8ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL3062187 | 0.81 | CYP3A4 (0.42) | MMP1MMP8ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL3062227 | 0.81 | CYP3A4 (0.42) | MMP1MMP8ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL3067845 | 0.78 | DPP7 (0.43) | DPP7ATMDPP4MMP1MMP2 | |
| SCHEMBL4618200 | 0.77 | MMP1 (0.41) | DPP7ATMDPP4MMP1MMP2 | |
| SCHEMBL29782266 | 0.77 | RBP4 (0.43) | DPP7ATMMMP1MMP2MMP8 | |
| SCHEMBL4616011 | 0.77 | MMP1 (0.41) | DPP7ATMDPP4MMP1MMP2 | |
| SCHEMBL16435188 | 0.77 | DPP7 (0.46) | DPP7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267719-A1 | Enhanced Indolinone Based Protein Kinase Inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-10-21 | — | — | US | disclosed |
| WO-2007081901-A2 | PYRIMIDINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267719-A1 | Enhanced Indolinone Based Protein Kinase Inhibitors | PHKG1, PHKG2, PRKCH | DPP7 2387/4885ATM 508/4885DPP4 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.